NOVO.B.DK

441.15

+1.85%↑

GMAB.DK

1,329.5

+1.14%↑

HLUNB.DK

36.04

+0.95%↑

ZEAL.DK

363.1

+2.45%↑

AMBUB.DK

100.8

+0.3%↑

NOVO.B.DK

441.15

+1.85%↑

GMAB.DK

1,329.5

+1.14%↑

HLUNB.DK

36.04

+0.95%↑

ZEAL.DK

363.1

+2.45%↑

AMBUB.DK

100.8

+0.3%↑

NOVO.B.DK

441.15

+1.85%↑

GMAB.DK

1,329.5

+1.14%↑

HLUNB.DK

36.04

+0.95%↑

ZEAL.DK

363.1

+2.45%↑

AMBUB.DK

100.8

+0.3%↑

NOVO.B.DK

441.15

+1.85%↑

GMAB.DK

1,329.5

+1.14%↑

HLUNB.DK

36.04

+0.95%↑

ZEAL.DK

363.1

+2.45%↑

AMBUB.DK

100.8

+0.3%↑

NOVO.B.DK

441.15

+1.85%↑

GMAB.DK

1,329.5

+1.14%↑

HLUNB.DK

36.04

+0.95%↑

ZEAL.DK

363.1

+2.45%↑

AMBUB.DK

100.8

+0.3%↑

Search

Coloplast A-S (Class B)

Open

609.2 0.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

603.2

Max

609.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

-132M

912M

Verkäufe

-96M

6.9B

KGV

Branchendurchschnitt

30.208

50.291

EPS

4.34

Dividendenrendite

3.61

Gewinnspanne

13.16

Angestellte

16,741

EBITDA

-42M

2.2B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.61%

2.40%

Nächstes Ergebnis

19. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-19B

138B

Vorheriger Eröffnungskurs

608.24

Vorheriger Schlusskurs

609.2

Coloplast A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Juni 2025, 23:49 UTC

Ergebnisse

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26. Juni 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26. Juni 2025, 21:30 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26. Juni 2025, 23:34 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26. Juni 2025, 23:33 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers Will No Longer Receive Earnings From BWP Management

26. Juni 2025, 23:32 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26. Juni 2025, 23:31 UTC

Akquisitionen, Fusionen, Übernahmen

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26. Juni 2025, 23:30 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26. Juni 2025, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26. Juni 2025, 23:19 UTC

Akquisitionen, Fusionen, Übernahmen

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26. Juni 2025, 22:06 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:15 UTC

Ergebnisse

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26. Juni 2025, 21:07 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26. Juni 2025, 21:07 UTC

Ergebnisse

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26. Juni 2025, 21:06 UTC

Akquisitionen, Fusionen, Übernahmen

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26. Juni 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26. Juni 2025, 20:52 UTC

Ergebnisse

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26. Juni 2025, 20:51 UTC

Ergebnisse

Correct: Nike 4Q Net $211M, Not $200M >NKE

26. Juni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Juni 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Coloplast A-S (Class B) Prognose

Kursziel

By TipRanks

11.86% Vorteil

12-Monats-Prognose

Durchschnitt 901.38 DKK  11.86%

Hoch 1,056 DKK

Tief 720 DKK

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Coloplast A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

2

Buy

4

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.